Semax vs Selank: Comparing Two Research Peptides

Semax and Selank are two synthetic heptapeptides developed by the same Russian research institute, but they are studied for different reasons. In the published literature, Semax (an analogue of the ACTH(4-10) fragment) is most often examined for neurotrophic and neuroprotective effects, with model work centred on brain-derived neurotrophic factor (BDNF) and ischaemia. Selank (derived from the immune peptide tuftsin) is most often examined for anxiolytic-like and immunomodulatory effects, with model work centred on GABAergic and serotonergic signalling. The two are sometimes investigated together because their studied mechanisms are largely distinct rather than overlapping.

For research use only — not for human or veterinary use. This article is an educational overview of laboratory and preclinical research. It is not medical, therapeutic, or dosing advice, and nothing here is a recommendation to administer any substance to humans or animals.

What are Semax and Selank?

Both compounds emerged from peptide research at the Institute of Molecular Genetics of the Russian Academy of Sciences, working with Russian pharmacology institutes. Each was designed around a naturally occurring peptide fragment, then modified with a C-terminal Pro-Gly-Pro motif intended to slow enzymatic breakdown and extend stability — a shared design idea that gives the two peptides a family resemblance despite their different parent molecules.

Semax: an ACTH(4-10) analogue

Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) based on the 4-10 fragment of adrenocorticotropic hormone (ACTH). The modification is reported to remove the hormonal (corticotropic) activity of the parent fragment while retaining the neuro-active properties that researchers were interested in. In Russia, Semax has been described in the literature and in regulatory approvals in the context of stroke and cognitive-disorder research, but that regulatory status does not apply elsewhere, and outside Russia it is handled as a research chemical.

Selank: a tuftsin-derived peptide

Selank is a heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) built from tuftsin, a naturally occurring tetrapeptide with immunomodulatory activity, again extended with the Pro-Gly-Pro tail. Because its parent molecule sits within the immune system, much of the Selank literature explores anxiolytic-like behaviour alongside effects on immune signalling — a lineage that distinguishes it from Semax.

What is the Semax vs Selank difference in mechanism?

The clearest way to separate the two research peptides is by the pathways that laboratory studies have focused on. These are described here strictly as reported findings in cell and animal models, not as established human effects.

• Semax — neurotrophic and neuroplasticity models. Studies report that Semax can increase expression of neurotrophic factors, particularly BDNF and nerve growth factor (NGF), and their receptors (such as TrkB) in nerve and glial cell cultures and in rat brain regions including the hippocampus and basal forebrain. This is linked in the literature to downstream signalling associated with neuronal survival and synaptic plasticity.
• Semax — ischaemia models. A substantial body of Russian preclinical work has examined Semax in models of cerebral ischaemia, reporting modulation of neurotrophic and vascular factors and effects on neuronal survival under low-oxygen conditions.
• Selank — GABAergic and serotonergic models. Research reports that Selank can alter expression of genes tied to GABAergic neurotransmission and influence GABA-A receptor subunit expression, as well as modulate serotonin metabolism — changes discussed as a possible basis for anxiolytic-like behaviour without direct receptor agonism.
• Selank — enkephalin and immune signalling. Consistent with its tuftsin lineage, studies describe inhibition of enkephalin-degrading enzymes (which may stabilise endogenous regulatory peptides) and modulation of pro-inflammatory cytokines under stress conditions in animal models.

In short: the Semax literature leans toward neurotrophic and neuroprotective questions, while the Selank literature leans toward anxiolytic-like and immunomodulatory questions. That difference in research focus is the core of the Semax vs Selank distinction.

What does the research evidence actually show — and where are its limits?

Both peptides have a real, but constrained, evidence base, and it is important to read it critically. Several limitations recur across the nootropic peptides research on Semax and Selank.

• Much of it is preclinical. A large share of the mechanistic evidence comes from cell cultures and rodent models, which do not reliably translate to humans.
• Human data is limited and geographically concentrated. The clinical literature is dominated by a relatively small number of Russian research groups and is largely published in Russian-language journals. Reported trials tend to have small sample sizes by modern standards.
• Independent replication is sparse. Large, randomised, placebo-controlled trials conducted by independent groups outside that network are largely absent, so many findings remain unreplicated in the wider literature.
• Regulatory status is not global. Approval or clinical use of these peptides within Russia does not indicate approval, safety, or efficacy for humans in Australia or most other jurisdictions.

For researchers, this means treating both compounds as subjects of ongoing investigation with genuinely open questions, not as settled interventions. The honest summary is that the mechanistic work is interesting and reasonably consistent, while the human evidence is thin and would benefit from independent, well-powered trials.

Why are Semax and Selank sometimes studied together?

Because their studied mechanisms are largely complementary rather than duplicative, some research and supplier catalogues pair them — including as a combined Semax 10mg + Selank 10mg research blend. The rationale discussed in the literature is that Semax's neurotrophic focus and Selank's anxiolytic-like and immunomodulatory focus address different systems, making them a natural comparison pair for experimental design. It is worth stressing that combining research peptides does not add or validate any human effect; a blend simply provides both peptides for laboratory use, and any interaction between them remains a research question rather than an established outcome.

How should researchers approach these peptides?

As with any research chemical, the appropriate framing is careful experimental handling, accurate record-keeping, and awareness of the evidence limits above. These are research reagents, not medicines or nootropic supplements, and no part of this comparison should be read as guidance to administer them. Researchers comparing the two typically do so on the basis of the mechanism they are investigating — neurotrophic and neuroprotective questions for Semax, anxiolytic-like and immunomodulatory questions for Selank.

You can review individual specifications for Semax and Selank, or browse the full range in the shop.

For research use only — not for human or veterinary use.